Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238491 | 1.00 | ALDH1A1 (0.66) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL11143982 | 0.84 | PTGS2 (0.57) | KDM4ESMN1; SMN2LMNATLR4TLR2 | |
| SCHEMBL10829207 | 0.82 | PTGS2 (0.47) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2349067 | 0.81 | TLR4 (0.64) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| Formic Acid SCHEMBL27325993 | 0.80 | TLR4 (0.48) | ALDH1A1KDM4ESMN1; SMN2LMNATLR4 | |
| SCHEMBL8551768 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL347528 | 0.79 | ALDH1A1 (1.00) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL10753672 | 0.79 | PTGS2 (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNATLR4 | |
| SCHEMBL15177156 | 0.79 | KDM4E (0.47) | ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL147539 | 0.78 | LOXL2 (0.52) | ALDH1A1KDM4ESMN1; SMN2LMNATLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568690-A1 | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers | Euro-Celtique S.A. (LU) | 2005-08-31 | — | — | EP | claimed |
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6638947-B2 | Blockers of sodium channels; treatment of neuronal damage following global and focal ischemia, treatment or prevention of neurodegenerative conditions, pain | EURO-CELTIQUE S.A. (LU) | 2003-10-28 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| CN-107011251-B | Synthesis method and application of 2- (2-chlorophenoxy) pyridine compound | 温州医科大学 | 2020-08-11 | — | — | CN | disclosed |
| US-10450292-B2 | Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols | Rutgers, The State University of New Jersesy (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190023682-A1 | INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-24 | — | — | US | disclosed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1997026252-A1 | INSECTICIDAL N-HETEROCYCLYLALKYL- OR N-[(POLYCYCLYL)-ALKYL]-N'-SUBSTITUTED PIPERAZINES | FMC CORPORATION (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023682-A1 | INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS | RNGTT, ELL, PGLS | ALDH1A1 1227/4885KDM4E 426/4885SMN1; SMN2 4815/4885 |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885KDM4E 3771/4885SMN1; SMN2 87/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885KDM4E 3771/4885SMN1; SMN2 87/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | ALDH1A1 97/4885KDM4E 3849/4885SMN1; SMN2 78/4885 |
| US-10450292-B2 | Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols | RNGTT, ELL, PGLS | ALDH1A1 1227/4885KDM4E 426/4885SMN1; SMN2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.